Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
Journal Paper/Review - Apr 29, 2022
Zeitlberger A M, Putora P M, Hofer S, Schucht P, Migliorini D, Hottinger A F, Roelcke U, Läubli H, Spina P, Bozinov Oliver, Weller M, Neidert M, Hundsberger Thomas
Glioblastoma is the most common malignant primary brain tumour in adults and driven by various genomic alterations. Next generation sequencing (NGS) provides timely information about the genetic landscape of tumours and might detect targetable mutations. To date, differences exist in the application and NGS assays used as it remains unclear to what extent these variants may affect clinical decision making. In this survey-based study, we investigated the use of NGS in adult patients with glioblastoma in Switzerland.